NASDAQ$MBRX
Moleculin Biotech Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Moleculin reported no revenue and a net loss in Q1 2025 while progressing its clinical development pipeline.
Moleculin Biotech reported a net loss of $6.4 million in Q1 2025 with no revenue, while continuing progress on its Annamycin trials for AML and STS lung metastases. Research and development expenses decreased year-over-year, and the company held $7.7 million in cash and equivalents as of quarter end.
- No revenue was reported for Q1 2025.
- Net loss totaled $6.4 million compared to $5.0 million in Q1 2024.
- Cash and cash equivalents stood at $7.7 million at the end of Q1.
- Enrollment continued in the pivotal Phase 3 MIRACLE trial for Annamycin.
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Moleculin expects continued clinical advancement in 2025, with multiple data readouts planned, subject to securing additional financing.
Tailwinds
- Enrollment and dosing in MIRACLE trial are underway.
- EMA approval expands the trial to 9 EU countries.
- Final data from the STS lung metastases trial expected by mid-2025.
- WP1066 trials progressing through external partnerships.
- Annamycin has multiple orphan drug designations and Fast Track Status.
Headwinds
- No revenue generation in the quarter.
- Ongoing net losses highlight continued cash burn.
- Funding only supports operations into Q3 2025.
- Dependent on additional financing to sustain trials.
- Regulatory approvals for further trial phases still pending.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.2%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-5.3%
Avg return
30 days after
32%
13 / 41 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | +9.8% | — | |
| Q4 2025 | +0.0% | +20.9% | +17.5% | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.1% | -99.7% | |
| Q4 2020 | -1.5% | -6.6% | -11.6% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro